LONDON, Feb. 15, 2017 /PRNewswire/ --Strong Focus on Digital Footprint and Beyond-the-pill Services Propel Companies to Innovate and Stay on the Growth Trajectory
Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing European pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key insights on the transforming pharmaceutical value chain, with the adoption of technology and shift towards digitalisation of key processes across drug development and manufacturing. It analyzes the dynamics catalyzing growth, profiles organizations presenting significant growth opportunities, and outlines innovative industry trends of key participants who play a vital role in the pharmaceutical landscape. The research covers the top 5 European pharmaceutical companies, based on their industry position. The companies included in the study are Bayer, AstraZeneca, Roche, Novartis, and Sanofi. These companies are benchmarked across 5 key growth levers, namely core areas of focus, digital footprint, value chain excellence, strategic collaborations and partnerships, and beyond-the-pill services and solutions. Highlights of the company profiles include:
- Company snapshot - Performance analysis (market revenue forecast) - Portfolio analysis - Key marketed products and patent expiry - SWOT analysis - Strategic analysis of growth leversDownload the full report: https://www.reportbuyer.com/product/4683681/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/game-changing-strategies-of-european-pharma-companies-300408235.html
SOURCE ReportBuyer
